Parameter | Patients with IPF (n = 41) | Patients with CPFE (n = 21) | p-value |
---|---|---|---|
Sex | |||
Male/Female | 34/7 (83%/17%) | 19/2 (91%/9%) | 0.676 |
Age (y) | 71 (67–75) | 74 (69–76) | 0.14 |
Cigarette smoking (pack-years) | 32 (0.875–44.75) (n = 38) | 51(29.5–69) (n = 19) | 0.0058 |
Patients using corticosteroid drugs | 8 (19.5%) | 6 (28.6%) | 0.419 |
Patients using immunosuppressant drugs | 1 (2%) | 1 (4.8%) | 0.788 |
Patients using antifibrotic drugs (e.g. pirfenidone or nintedanib) | 10 (24.4%) | 3 (14.3%) | 0.552 |
Patients receiving NAC inhalation | 1 (0.2%) | 0(0%) | 0.73 |
Patients receiving supplemental oxygen | 12 (29.3%) | 9 (42.9%) | 0.285 |
LAA score (points) | 1 (0–3) | 10 (9–15) | < 0.001 |
%FVC (%) | 64.5 (53.2–80.9) (n = 28) | 79.3 (73.7–90.1) (n = 17) | 0.0069 |
%DLco (%) | 39.8 (29.8–51.9) (n = 21) | 35.4 (30.6–41.1) (n = 14) | 0.2461 |
FEV1 / FVC | 84.75(83–88.4) | 81.2(72.3–87.5) | 0.018 |
GAP score (points) | 4.5 (4–6) (n = 22) | 4.5 (4–5) (n = 14) | 0.58 |
CPI | 55.4 (45.4–61.8) (n = 22) | 52.6 (46.3–58.0) (n = 14) | 0.41 |
P/F ratio (Torr) | 331 (291–358) (n = 26) | 328 (315–366) (n = 17) | 0.555 |
TR-PG (mmHg) | 22.3 (15.5–31.2) (n = 15) | 22.6 (18.1–26.1) (n = 6) | 0.969 |
WBC count (/mm3) | 7805 (6575–8337.5) (n = 33) | 6780 (6270–8000) (n = 20) | 0.238 |
CRP (mg/dL) | 0.14 (0.06–0.26) (n = 29) | 0.11 (0.04–0.26) (n = 19) | 0.51 |
LDH (IU/L) | 222 (201–267) (n = 29) | 234 (207–252) (n = 19) | 0.78 |
KL-6 (U/mL) | 1246 (899–1494) (n = 33) | 636.5 (442–1102) (n = 19) | 0.004 |
RF (IU/mL) < 10 /≥10 | 25/11 (n = 36) a | 9/8 (n = 17)b | 0.242 |
ANA < 1:40 / ≥1:40 | 20/15 (n = 35) c | 9/9 (n = 18) d | 0.621 |